The response mechanism may involve the establishment of a “drug-free” environment, leading to a decrease in the number of heterogeneous tumor cells previously exposed to BRAF and MEK inhibitors, ultimately resulting in a successful re-challenge for certain patients [143]. This evidence concerns the gene BRAF and neoplasm.